Video

ecancer's extensive video archive features interviews, panel discussions and conference coverage on almost every topic in oncology.

Becotarug plus osimertinib shows survival benefit in EGFR exon 20 insertion lung cancer

Dr Jinhui Xue - Sun Yat-sen University Cancer Center, Guangzhou, China
Becotarug plus osimertinib shows survival benefit in EGFR exon 20 insertion lung cancer ( Dr Jinhui Xue - Sun Yat-sen University Cancer Center, Guangzhou, China )
15 Apr 2026

TQB2922 combination shows high response rates in EGFR-mutant lung cancer after tyrosine kinase inhibitor resistance

Dr Jinhui Xue - Sun Yat-sen University Cancer Center, Guangzhou, China
TQB2922 combination shows high response rates in EGFR-mutant lung cancer after tyrosine kinase inhibitor resistance ( Dr Jinhui Xue - Sun Yat-sen University Cancer Center, Guangzhou, China )
15 Apr 2026

SHR-A2009 plus EGFR tyrosine kinase inhibitor shows promising activity in EGFR-mutant lung cancer

Prof Yi-Long Wu - Guangdong Lung Cancer Institute, Guangzhou, China
SHR-A2009 plus EGFR tyrosine kinase inhibitor shows promising activity in EGFR-mutant lung cancer ( Prof Yi-Long Wu - Guangdong Lung Cancer Institute, Guangzhou, China )
14 Apr 2026

Sevabertinib shows manageable diarrhoea without impacting efficacy in HER2-mutant lung cancer

Prof Nicolas Girard - Institut Curie, Paris, France
Sevabertinib shows manageable diarrhoea without impacting efficacy in HER2-mutant lung cancer ( Prof Nicolas Girard - Institut Curie, Paris, France )
14 Apr 2026

Subcutaneous amivantamab plus lazertinib shows durable responses in EGFR-mutant advanced lung cancer

Prof Nicolas Girard - Institut Curie, Paris, France
Subcutaneous amivantamab plus lazertinib shows durable responses in EGFR-mutant advanced lung cancer ( Prof Nicolas Girard - Institut Curie, Paris, France )
14 Apr 2026

Distinct lung microbiome patterns identified in Portuguese patients with lung cancer

Dr Telma Sequeira - CUF Tejo, Lisbon, Portugal
Distinct lung microbiome patterns identified in Portuguese patients with lung cancer ( Dr Telma Sequeira - CUF Tejo, Lisbon, Portugal )
14 Apr 2026

Artificial intelligence PD-L1 scoring matches pathologists and improves reproducibility in lung cancer testing

Prof Fred Hirsch - Icahn School of Medicine at Mount Sinai, New York, USA
Artificial intelligence PD-L1 scoring matches pathologists and improves reproducibility in lung cancer testing ( Prof Fred Hirsch - Icahn School of Medicine at Mount Sinai, New York, USA )
14 Apr 2026

T-cell engagers in lung cancer: Strategies to prevent and manage toxicities

Dr Myung-Ju Ahn - Sungkyunkwan University School of Medicine, Seoul, South Korea
T-cell engagers in lung cancer: Strategies to prevent and manage toxicities ( Dr Myung-Ju Ahn - Sungkyunkwan University School of Medicine, Seoul, South Korea )
14 Apr 2026

Education and training in breast cancer care

Dr Alexandru Eniu, Danny Burke & Dr Montassar Ghalleb
Education and training in breast cancer care ( Dr Alexandru Eniu, Danny Burke & Dr Montassar Ghalleb )
14 Apr 2026

Low-dose CT screening reduces lung cancer mortality and improves survival in broad populations

Dr Caichen Li - Guangzhou Medical University, Guangzhou, China
Low-dose CT screening reduces lung cancer mortality and improves survival in broad populations ( Dr Caichen Li  - Guangzhou Medical University, Guangzhou, China )
13 Apr 2026

Cracking the code: Bispecific immunotherapy in small cell lung cancer

Prof Helena Linardou - Metropolitan Hospital, Athens, Greece
Cracking the code: Bispecific immunotherapy in small cell lung cancer ( Prof Helena Linardou - Metropolitan Hospital, Athens, Greece )
13 Apr 2026

ATR inhibitor plus durvalumab does not improve survival over docetaxel in advanced NSCLC

Prof Benjamin Besse - Institut Gustave Roussy, Villejuif, France
ATR inhibitor plus durvalumab does not improve survival over docetaxel in advanced NSCLC ( Prof Benjamin Besse - Institut Gustave Roussy, Villejuif, France )
13 Apr 2026